PT3134386T - Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer - Google Patents

Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer

Info

Publication number
PT3134386T
PT3134386T PT157263625T PT15726362T PT3134386T PT 3134386 T PT3134386 T PT 3134386T PT 157263625 T PT157263625 T PT 157263625T PT 15726362 T PT15726362 T PT 15726362T PT 3134386 T PT3134386 T PT 3134386T
Authority
PT
Portugal
Prior art keywords
alloesteric
isoindoline
derivatives
treatment
receptor positive
Prior art date
Application number
PT157263625T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53276227&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3134386(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of PT3134386T publication Critical patent/PT3134386T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
PT157263625T 2014-04-23 2015-04-22 Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer PT3134386T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014089585 2014-04-23

Publications (1)

Publication Number Publication Date
PT3134386T true PT3134386T (pt) 2020-08-25

Family

ID=53276227

Family Applications (1)

Application Number Title Priority Date Filing Date
PT157263625T PT3134386T (pt) 2014-04-23 2015-04-22 Derivados de isoindolina-1-ona com atividade moduladora alostérica positiva para o recetor m1 muscarínico colinérgico para o tratamento da doença de alzheimer

Country Status (36)

Country Link
US (16) US9315458B2 (enExample)
EP (1) EP3134386B1 (enExample)
JP (1) JP6517239B2 (enExample)
KR (1) KR102349237B1 (enExample)
CN (1) CN106536508B (enExample)
AR (1) AR100154A1 (enExample)
AU (1) AU2015250610B2 (enExample)
BR (1) BR112016024472B1 (enExample)
CA (1) CA2946519C (enExample)
CL (1) CL2016002661A1 (enExample)
CR (1) CR20160544A (enExample)
CY (1) CY1123569T1 (enExample)
DK (1) DK3134386T3 (enExample)
DO (1) DOP2016000286A (enExample)
EA (1) EA030373B1 (enExample)
EC (1) ECSP16090152A (enExample)
ES (1) ES2811088T3 (enExample)
HR (1) HRP20201171T1 (enExample)
HU (1) HUE050543T2 (enExample)
IL (1) IL248393B (enExample)
LT (1) LT3134386T (enExample)
MX (1) MX373274B (enExample)
MY (1) MY195742A (enExample)
NZ (1) NZ725921A (enExample)
PE (1) PE20161400A1 (enExample)
PH (1) PH12016502095B1 (enExample)
PL (1) PL3134386T3 (enExample)
PT (1) PT3134386T (enExample)
RS (1) RS60524B1 (enExample)
SG (1) SG11201608785PA (enExample)
SI (1) SI3134386T1 (enExample)
TN (1) TN2016000455A1 (enExample)
TW (1) TWI664165B (enExample)
UA (1) UA122391C2 (enExample)
UY (1) UY36091A (enExample)
WO (1) WO2015163485A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
EA030373B1 (ru) 2014-04-23 2018-07-31 Такеда Фармасьютикал Компани Лимитед Изоиндолин-1-оновые производные в качестве положительных аллостерических модуляторов холинергического мускаринового m1 рецептора для лечения болезни альцгеймера
SI3674302T1 (sl) 2014-04-23 2023-07-31 Incyte Holdings Corporation 1h-pirolo(2,3-c)piridin-7(6h)-oni in pirazolo(3,4-c)piridin-7(6h)-oni kot zaviralci proteinov bet
US10208046B2 (en) 2014-05-16 2019-02-19 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
US10214508B2 (en) 2014-06-13 2019-02-26 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
EP3313836B1 (en) 2015-06-26 2020-11-11 Takeda Pharmaceutical Company Limited 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
WO2017069173A1 (ja) 2015-10-20 2017-04-27 武田薬品工業株式会社 複素環化合物
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
WO2017107089A1 (en) * 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
JP6860551B2 (ja) * 2016-03-11 2021-04-14 武田薬品工業株式会社 芳香環化合物
CR20190027A (es) 2016-06-20 2019-05-16 Incyte Corp Formas sólidas cristalinas de un inhibidor de bet
WO2018005249A1 (en) * 2016-06-28 2018-01-04 Merck Sharp & Dohme Corp. Benzoisoquinolinone m1 receptor positive allosteric modulators
WO2018159639A1 (ja) 2017-02-28 2018-09-07 武田薬品工業株式会社 複素環化合物の製造方法
WO2018194181A1 (en) 2017-04-18 2018-10-25 Takeda Pharmaceutical Company Limited Heterocyclic compounds useful as modulators of acetylcholine receptors
WO2018212312A1 (ja) 2017-05-19 2018-11-22 武田薬品工業株式会社 スクリーニング方法
US10945771B2 (en) 2017-06-09 2021-03-16 Merck Sharp & Dohme Corp. Azabicyclo[4.1.0]heptane allosteric modulators of the M4 muscarinic acetylcholine receptor
PT3643718T (pt) 2017-06-20 2023-10-26 Takeda Pharmaceuticals Co Composto heterocíclico e seu uso como modulador alostérico positivo do recetor muscarínico colinérgico m1
AU2018289939B2 (en) 2017-06-20 2022-06-16 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) * 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
JP2020158392A (ja) * 2017-07-25 2020-10-01 Ａｇｃ株式会社 フルオロフェノール誘導体の製造方法及び新規なフルオロ化合物
US12156871B2 (en) * 2017-11-23 2024-12-03 Suven Life Sciences Limited Substituted azacycles as muscarinic M1 receptor positive allosteric modulators
JP7443238B2 (ja) * 2018-09-28 2024-03-05 武田薬品工業株式会社 複素環化合物
EP3858838A4 (en) 2018-09-28 2022-06-29 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP7446232B2 (ja) 2018-09-28 2024-03-08 武田薬品工業株式会社 縮合環化合物
CN113329679A (zh) * 2018-12-28 2021-08-31 卢遂显 检测治疗和预防神经发育障碍的方法
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CA3185726A1 (en) * 2020-07-29 2022-02-03 Dae Kyu Choi Dual regulator for mglur5 and 5-ht2a receptors and use thereof
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators
WO2025231255A1 (en) * 2024-05-01 2025-11-06 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m1

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4416647Y1 (enExample) 1965-05-26 1969-07-18
JPS60172704A (ja) 1984-02-14 1985-09-06 Mitsuwa Seiki Co Ltd 流体アクチユエ−タの制御方法
JP2699511B2 (ja) 1988-01-29 1998-01-19 武田薬品工業株式会社 置換アミン類
US5538983A (en) 1990-05-16 1996-07-23 The Rockefeller University Method of treating amyloidosis by modulation of calcium
TW219935B (enExample) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
JPH06220044A (ja) * 1991-12-25 1994-08-09 Mitsubishi Kasei Corp ベンズアミド誘導体
GB9409150D0 (en) 1994-05-09 1994-06-29 Black James Foundation Cck and gastrin receptor ligands
US5744476A (en) 1994-06-27 1998-04-28 Interneuron Pharmaceuticals, Inc. Dopamine D1 agonists for the treatment of dementia
JP2992677B2 (ja) 1995-06-05 1999-12-20 武田薬品工業株式会社 骨形成促進医薬組成物
WO1998030243A1 (en) 1997-01-08 1998-07-16 Warner-Lambert Company Acetylcholinesterase inhibitors in combination with muscarinic agonists for the treatment of alzheimer's disease
US7084126B1 (en) 2000-05-01 2006-08-01 Healthpartners Research Foundation Methods and compositions for enhancing cellular function through protection of tissue components
EP1316203A2 (en) 2000-06-30 2003-06-04 Eli Lilly And Company Combination for treating psychoses, comprising an antipsychotic and a muscarinic agonist
JP2004532200A (ja) 2001-03-15 2004-10-21 サエジス ファーマシューティカルズ， インコーポレイテッド 全身性ストレスの後に認識機能を回復するための方法
WO2002081447A1 (en) 2001-04-06 2002-10-17 Daewoong Pharmaceutical Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isothiazolinone derivatives and the use thereof
WO2002081446A1 (en) 2001-04-06 2002-10-17 Daewoong Co., Ltd. 3-cyclopentyloxy-4-methoxyphenyl-isoindolinone derivatives and the use thereof
US20040023951A1 (en) 2001-06-18 2004-02-05 Bymaster Franklin Porter Combination therapy for treatment of psychoses
DE10137163A1 (de) * 2001-07-30 2003-02-13 Bayer Ag Substituierte Isoindole und ihre Verwendung
US20040044023A1 (en) 2002-08-30 2004-03-04 Marc Cantillon Compositions and methods for treating or preventing memory impairment
US20060233843A1 (en) 2003-02-19 2006-10-19 Conn P J Treatment of psychosis with a muscarinic m1 receptor ectopic activator
EP1613321A2 (en) 2003-03-28 2006-01-11 Acadia Pharmaceuticals Inc. Muscarinic m1 receptor agonists for pain management
US20040266659A1 (en) 2003-06-27 2004-12-30 Stephen LaBerge Substances that enhance recall and lucidity during dreaming
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
EP1885708A2 (en) 2005-04-15 2008-02-13 Board of Trustees of Michigan State University Gpcr modulators
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US20110319386A1 (en) 2005-08-26 2011-12-29 Braincells Inc. Neurogenesis by muscarinic receptor modulation
US7678363B2 (en) 2005-08-26 2010-03-16 Braincells Inc Methods of treating psychiatric conditions comprising administration of muscarinic agents in combination with SSRIs
WO2007044937A2 (en) 2005-10-13 2007-04-19 President And Fellows Of Harvard College Compositions and methods to modulate memory
GB0607952D0 (en) 2006-04-21 2006-05-31 Minster Res Ltd Novel treatment
GB0607949D0 (en) 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
GB0607946D0 (en) 2006-04-21 2006-05-31 Minster Res The Ltd Mono and combination therapy
TW200806625A (en) 2006-05-26 2008-02-01 Astrazeneca Ab Therapeutic compounds
US8143284B2 (en) 2006-10-05 2012-03-27 Abbott Laboratories Poly(ADP-ribose)polymerase inhibitors
US8618074B2 (en) 2007-03-15 2013-12-31 Board Of Regents Of The University Of Texas System GPCR enhanced neuroprotection to treat brain injury
WO2009039460A2 (en) 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. Co-administration of pimavanserin with other agents
CA2700332A1 (en) 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2009039635A1 (en) * 2007-09-24 2009-04-02 Painceptor Pharma Corporation Methods of modulating neurotrophin-mediated activity
WO2009042907A1 (en) * 2007-09-27 2009-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2010042603A1 (en) 2008-10-08 2010-04-15 Cingulate Neuro Therapeutics, Llc Amyloid and depression
WO2010096338A1 (en) 2009-02-23 2010-08-26 Merck Sharp & Dohme Corp. PYRAZOLO [4,3-c] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
SG174220A1 (en) 2009-03-05 2011-10-28 Mithridion Inc Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
ES2759751T3 (es) 2009-07-14 2020-05-12 Nerviano Medical Sciences Srl 3-oxo-2,3-dihidro-1H-isoindol-4-carboxamidas
CA2804215C (en) 2009-07-22 2019-10-01 Eric Elenko Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
RU2573569C2 (ru) 2009-12-22 2016-01-20 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона
US8314120B2 (en) * 2010-03-30 2012-11-20 Abbott Gmbh & Co. Kg Small molecule potentiators of metabotropic glutamate receptors
WO2012003147A1 (en) 2010-07-01 2012-01-05 Merck Sharp & Dohme Corp. Isoindolone m1 receptor positive allosteric modulators
US9549928B2 (en) 2011-04-29 2017-01-24 The University Of Toledo Muscarinic agonists as enhancers of cognitive flexibility
WO2012158475A1 (en) * 2011-05-17 2012-11-22 Merck Sharp & Dohme Corp. N-linked lactam m1 receptor positive allosteric modulators
WO2012170599A1 (en) 2011-06-10 2012-12-13 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
HUE031313T2 (hu) 2011-10-28 2017-07-28 Univ Vanderbilt Szubsztituált 2-(4-heterociklilbenzil)izoindolin-1-on analógok mint muszkarin acetilkolin receptor M1 pozitív allosztérikus modulátorai
US9403802B2 (en) 2012-03-02 2016-08-02 Takeda Pharmaceutical Company Limited Heterocyclic compound and use therefor
US20130289019A1 (en) 2012-04-26 2013-10-31 Amazing Grace, Inc. Methods of treating behaviorial and/or mental disorders
US9777005B2 (en) 2012-11-19 2017-10-03 Takeda Pharmaceutical Company Limited Bicyclic heterocyclic compound containing a substituted pyrrole ring
TW201512197A (zh) 2013-08-30 2015-04-01 Hoffmann La Roche 吡咯并吡啶或吡唑并吡啶衍生物
EP3049391B1 (en) 2013-09-27 2018-12-26 F.Hoffmann-La Roche Ag Indole and indazole derivatives
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
EA030373B1 (ru) * 2014-04-23 2018-07-31 Такеда Фармасьютикал Компани Лимитед Изоиндолин-1-оновые производные в качестве положительных аллостерических модуляторов холинергического мускаринового m1 рецептора для лечения болезни альцгеймера
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2018122845A1 (en) 2016-12-29 2018-07-05 Rvx Therapeutics Ltd. Methods and compositions for potentiating cns drugs and reducing their side effects

Also Published As

Publication number Publication date
MX373274B (es) 2020-04-16
US10457670B2 (en) 2019-10-29
PH12016502095B1 (en) 2024-07-03
ECSP16090152A (es) 2017-08-31
HUE050543T2 (hu) 2020-12-28
EP3134386B1 (en) 2020-05-20
US20170258764A1 (en) 2017-09-14
US20190241547A1 (en) 2019-08-08
US20160152598A1 (en) 2016-06-02
US9655881B2 (en) 2017-05-23
CN106536508A (zh) 2017-03-22
TW201623233A (zh) 2016-07-01
MY195742A (en) 2023-02-08
CA2946519A1 (en) 2015-10-29
US9499516B2 (en) 2016-11-22
US9662316B2 (en) 2017-05-30
WO2015163485A1 (en) 2015-10-29
RS60524B1 (sr) 2020-08-31
ES2811088T3 (es) 2021-03-10
IL248393A0 (en) 2016-11-30
US20170100373A1 (en) 2017-04-13
AU2015250610A1 (en) 2016-12-01
US20240109874A1 (en) 2024-04-04
PH12016502095A1 (en) 2017-01-09
DK3134386T3 (da) 2020-08-17
KR102349237B1 (ko) 2022-01-07
CA2946519C (en) 2022-07-19
JP6517239B2 (ja) 2019-05-22
KR20160143852A (ko) 2016-12-14
US20220411413A1 (en) 2022-12-29
US20170027921A1 (en) 2017-02-02
US20170266162A1 (en) 2017-09-21
BR112016024472A2 (pt) 2017-08-15
US10865200B2 (en) 2020-12-15
US20180000780A1 (en) 2018-01-04
PE20161400A1 (es) 2017-01-06
BR112016024472B1 (pt) 2023-02-14
US20180346452A1 (en) 2018-12-06
NZ725921A (en) 2023-09-29
MX2016013810A (es) 2017-03-09
SG11201608785PA (en) 2016-11-29
CL2016002661A1 (es) 2017-03-24
TN2016000455A1 (en) 2018-04-04
PL3134386T3 (pl) 2020-11-16
US20160152603A1 (en) 2016-06-02
TWI664165B (zh) 2019-07-01
US9675597B2 (en) 2017-06-13
BR112016024472A8 (pt) 2021-06-29
EA201692132A1 (ru) 2017-04-28
IL248393B (en) 2019-10-31
US20170044143A1 (en) 2017-02-16
HRP20201171T1 (hr) 2020-11-13
EA030373B1 (ru) 2018-07-31
AU2015250610B2 (en) 2019-02-07
LT3134386T (lt) 2020-08-10
US9789084B2 (en) 2017-10-17
US20170216255A1 (en) 2017-08-03
CN106536508B (zh) 2019-08-09
US20210009572A1 (en) 2021-01-14
JP2017513894A (ja) 2017-06-01
US9518042B2 (en) 2016-12-13
EP3134386A1 (en) 2017-03-01
US9868725B2 (en) 2018-01-16
UY36091A (es) 2015-11-30
SI3134386T1 (sl) 2020-10-30
US9789083B2 (en) 2017-10-17
AR100154A1 (es) 2016-09-14
US9315458B2 (en) 2016-04-19
US9775827B2 (en) 2017-10-03
US20170100384A1 (en) 2017-04-13
CR20160544A (es) 2017-01-13
CY1123569T1 (el) 2022-03-24
UA122391C2 (uk) 2020-11-10
DOP2016000286A (es) 2017-02-15
US20150307451A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
IL248393B (en) Isoindoline-1-one derivatives for positive allosteric modulation activity for muscarinic cholinergic 1m receptor for the treatment of Alzheimer's disease
EP3212233A4 (en) Combination therapy for treatment of disease
IL247452A0 (en) Compounds for treatment of complement mediated disorders
IL252309B (en) Compressed bicyclic compounds for disease treatment
SG11201609770TA (en) Combination therapies for the treatment of cancer
EP3180020A4 (en) Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases
IL249480A0 (en) Optogenetic treatments for movement disorders
EP3148532A4 (en) Pharmaceutical combination for the treatment of cancer
IL252849B (en) Compressed bicyclic compounds for disease treatment
EP3140417A4 (en) Foetal polymix of mesenchymal stem cells under hypoxic conditions for the treatment of clinical disorders
IL249502A0 (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of protein-associated diseases
SMT202100082T1 (it) Composti eteroarilici per il trattamento di malattie oftalmiche
IL248779A0 (en) Pharmaceutical preparations for the treatment of infectious diseases
EP3137907A4 (en) Methods and compositions for the diagnosis and treatment of kawasaki disease
SG11201702700UA (en) Methods for the treatment of peri-implantitis
EP3169405A4 (en) Methods, compounds, and compositions for the treatment of musculoskeletal diseases
EP3100724A4 (en) Medicine for preventing ischemic diseases
EP3096775A4 (en) Socs mimetics for the treatment of diseases
HUE070257T2 (hu) Vegyületek a lipofuscinhoz kapcsolódó betegségek kezelésére
PL3125818T3 (pl) System mocujący do implantów stomatologicznych
SG11201703330YA (en) Iminosugars useful for the treatment of viral diseases
PL3164110T3 (pl) Kompozycje farmaceutyczne do leczenia łuszczycy
AU2014902717A0 (en) Patients Bed
HK1236134A1 (en) Pharmaceutical combination for the treatment of cancer
HK1238246A (en) Iminosugars useful for the treatment of viral diseases